NRx Defense Systems Tapped by DARPA for SPARC-TMS Trial Negotiation; FDA Clears Phase 2/3 Protocol
NRXP has more than doubled off its 52-week low of $1.62.
Summary
NRx Pharmaceuticals' defense subsidiary, NRXD, has been selected by DARPA to negotiate a potential award for a Phase 2/3 clinical trial combining robotic TMS with NRX-101. The FDA has approved the trial protocol, and the study will be conducted at leading institutions including Harvard McLean and Walter Reed.
Key Events · Product Development and Regulatory · NRXP
-
DARPA Selects SPARC-TMS Proposal
On July 21, 2026, NRx Defense Systems (NRXD) received a letter from DARPA notifying the company that its SPARC-TMS proposal has been selected for negotiation of a potential award. This non-dilutive funding opportunity would support a clinical trial combining robotic TMS with NRX-101.
-
FDA Approves Phase 2/3 Trial Protocol
The FDA has approved the SPARC-TMS trial protocol as a Phase 2/3 study, now posted on clinicaltrials.gov (NCT07227103). The trial aims to demonstrate the efficacy of robotic-enabled TMS combined with NRX-101 in achieving remission from depression.
-
Prestigious Trial Sites Confirmed
The study is planned to be conducted at Harvard McLean Hospital, clinics operated by HOPE Therapeutics, and designated military treatment facilities including the Walter Reed National Military Medical Center.
-
NRX-101's Breakthrough Therapy Designation
NRX-101, the drug to be used in the trial, was previously awarded Breakthrough Therapy Designation by the FDA, underscoring its potential in treating depression.
Analysis · NRXP · Life Sciences
NRx's defense subsidiary, NRXD, has been selected by DARPA to negotiate a potential award for a clinical trial combining robotic TMS with NRX-101, a drug that already holds Breakthrough Therapy Designation. With the FDA's approval of the Phase 2/3 protocol, the trial will be conducted at prestigious sites including Harvard McLean and Walter Reed. This represents a significant validation of the company's neuroplasticity platform and opens a non-dilutive funding pathway through government contracts. Against the backdrop of a recent going-concern warning and heavy dilution, this milestone provides a tangible catalyst that could extend the cash runway and attract partnership interest.
At the time of this filing, NRXP was trading at $4.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $187.1M. The 52-week trading range was $1.62 to $5.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.